1. Home
  2. VIGL vs SRTS Comparison

VIGL vs SRTS Comparison

Compare VIGL & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • SRTS
  • Stock Information
  • Founded
  • VIGL 2020
  • SRTS 2010
  • Country
  • VIGL United States
  • SRTS United States
  • Employees
  • VIGL N/A
  • SRTS N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • SRTS Medical/Dental Instruments
  • Sector
  • VIGL Health Care
  • SRTS Health Care
  • Exchange
  • VIGL Nasdaq
  • SRTS Nasdaq
  • Market Cap
  • VIGL 89.3M
  • SRTS N/A
  • IPO Year
  • VIGL 2022
  • SRTS 2016
  • Fundamental
  • Price
  • VIGL $1.68
  • SRTS $4.72
  • Analyst Decision
  • VIGL Strong Buy
  • SRTS Strong Buy
  • Analyst Count
  • VIGL 5
  • SRTS 3
  • Target Price
  • VIGL $16.33
  • SRTS $13.00
  • AVG Volume (30 Days)
  • VIGL 159.5K
  • SRTS 115.8K
  • Earning Date
  • VIGL 03-13-2025
  • SRTS 05-08-2025
  • Dividend Yield
  • VIGL N/A
  • SRTS N/A
  • EPS Growth
  • VIGL N/A
  • SRTS 1266.06
  • EPS
  • VIGL N/A
  • SRTS 0.41
  • Revenue
  • VIGL N/A
  • SRTS $41,807,000.00
  • Revenue This Year
  • VIGL N/A
  • SRTS $9.09
  • Revenue Next Year
  • VIGL N/A
  • SRTS $22.30
  • P/E Ratio
  • VIGL N/A
  • SRTS $11.58
  • Revenue Growth
  • VIGL N/A
  • SRTS 71.31
  • 52 Week Low
  • VIGL $1.49
  • SRTS $3.09
  • 52 Week High
  • VIGL $6.06
  • SRTS $9.33
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 32.05
  • SRTS 43.79
  • Support Level
  • VIGL $1.74
  • SRTS $4.44
  • Resistance Level
  • VIGL $1.94
  • SRTS $4.93
  • Average True Range (ATR)
  • VIGL 0.16
  • SRTS 0.21
  • MACD
  • VIGL -0.02
  • SRTS 0.08
  • Stochastic Oscillator
  • VIGL 4.51
  • SRTS 55.56

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: